We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+15.53%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$254M
AUM Growth
-$32.6M
Cap. Flow
-$20.3M
Cap. Flow %
-8%
Top 10 Hldgs %
68.51%
Holding
44
New
8
Increased
7
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$9.69M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$8.8M
3
NTLA icon
Intellia Therapeutics
NTLA
+$8.27M
4
DERM
Dermira, Inc.
DERM
+$7.51M
5
AKAO
Achaogen Inc
AKAO
+$5.47M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$20.3M
2
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$10.5M
3
EPZM
Epizyme, Inc
EPZM
+$9.41M
4
AIMT
Aimmune Therapeutics
AIMT
+$7.07M
5
KITE
Kite Pharma, Inc.
KITE
+$6.89M

Sector Composition

Rank Sector Weight
1 Healthcare 86.15%
2 Miscellaneous 13.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$682M
$31.8M 12.53%
2,901,958
+440,626
+18% +$4.31M
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$24.4M 9.61%
439,385
+192,694
+78% +$9.69M
TVTX icon
3
Travere Therapeutics
TVTX
$6.19B
$21.8M 8.6%
1,225,084
– –
CYTK icon
4
Cytokinetics
CYTK
$10B
$20.3M 8.01%
2,139,697
+86,897
+4% +$713K
ASMB icon
5
Assembly Biosciences
ASMB
$694M
$16.3M 6.44%
245,264
+70,405
+40% +$4.62M
KYNB
6
Kyntra Bio
KYNB
$32.5M
$12.9M 5.1%
31,550
-3,000
-9% -$1.37M
XLRN
7
DELISTED
Acceleron Pharma
XLRN
$12.6M 4.98%
371,381
+101,092
+37% +$3.29M
GILD icon
8
CALL
Gilead Sciences
GILD
$181B
$12.5M 4.93%
150,000
– –
AGN
9
CALL
DELISTED
Allergan plc
AGN
$11.6M 4.56%
+50,000
New +$11.5M
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.51M 3.75%
+244,950
New +$8.8M
DERM
11
DELISTED
Dermira, Inc.
DERM
$7.96M 3.14%
+272,000
New +$7.51M
EPZM
12
DELISTED
Epizyme, Inc
EPZM
$7.73M 3.05%
755,046
-843,854
-53% -$9.41M
IRWD icon
13
CALL
Ironwood Pharmaceuticals
IRWD
$682M
$7.61M 3%
694,311
+336,111
+94% +$3.28M
KURA icon
14
Kura Oncology
KURA
$1.13B
$6.68M 2.63%
2,465,286
– –
NTLA icon
15
Intellia Therapeutics
NTLA
$1.8B
$6.63M 2.62%
+310,695
New +$8.27M
AKAO
16
DELISTED
Achaogen Inc
AKAO
$5.96M 2.35%
+1,571,708
New +$5.47M
ONC
17
BeOne Medicines Ltd
ONC
$41.5B
$5.23M 2.06%
175,380
+159,614
+1,012% +$4.68M
KIN
18
DELISTED
Kindred Biosciences, Inc.
KIN
$5.07M 2%
1,432,765
– –
NBRV
19
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.22M 1.66%
2,251
-580
-20% -$1.17M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.74B
$3.52M 1.39%
357,365
-153,464
-30% -$2.1M
COLL icon
21
Collegium Pharmaceutical
COLL
$786M
$3.34M 1.32%
281,776
-191,347
-40% -$3.16M
XNCR icon
22
Xencor
XNCR
$1.94B
$3.19M 1.26%
+168,000
New +$2.3M
ENTA icon
23
Enanta Pharmaceuticals
ENTA
$396M
$3.02M 1.19%
136,882
-103,501
-43% -$2.71M
EDIT icon
24
Editas Medicine
EDIT
$485M
$2.08M 0.82%
85,469
-2,452
-3% -$82.7K
ARRY
25
CALL
DELISTED
Array Biopharma Inc
ARRY
$1.85M 0.73%
520,000
– –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2016 Portfolio in Review

As of Q2 2016, EcoR1 Capital held 44 positions worth $254M, down 11% from $286M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

EcoR1 Capital withdrew a net $20.3M in Q2 2016, closing 12 positions and reducing 10 holdings. Its most notable exit was Five Prime Therapeutics, Inc., an estimated $20.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Intra-Cellular Therapies Inc. worth $9.51M.

  • EcoR1 Capital's largest Q2 2016 buy was Intra-Cellular Therapies Inc.: 244,950 shares worth $9.51M.
  • EcoR1 Capital added most to Lakefront Biotherapeutics American Depositary Shares in Q2 2016, an estimated $9.69M increase.
  • EcoR1 Capital's biggest Q2 2016 reduction was Epizyme, Inc, cutting an estimated $9.41M.
  • EcoR1 Capital fully exited Five Prime Therapeutics, Inc. in Q2 2016, selling an estimated $20.3M.
  • EcoR1 Capital's ten largest holdings make up 69% of its $254M portfolio in Q2 2016.
  • EcoR1 Capital opened 8 new positions and closed 12 in Q2 2016.
  • EcoR1 Capital's portfolio value fell 11% quarter-over-quarter to $254M.

Based on EcoR1 Capital's 13F filing for Q2 2016, filed 15 Aug 2016.